<DOC>
	<DOCNO>NCT00124514</DOCNO>
	<brief_summary>The purpose study test safety triptorelin use protection ovary ( pair female reproductive organ ) cyclophosphamide therapy systemic lupus erythematosus ( SLE ; lupus ) see effect ( good bad ) patient . The study do female patient diagnose systemic lupus erythematosus , young 21 year age , require intravenous cyclophosphamide control disease . Each patient study approximately 23 month , 4 month intravenous cyclophosphamide treatment complete . This study currently conduct 3 site across United States Brazil ( Los Angeles , Cincinnati San Paulo Brazil ) . A total 50 patient participate study . Each patient randomize ( assign ) one 5 group . Randomization mean patient put group completely chance . It like flip coin . Neither patient study staff know group patient . The patient 20 % chance place group . Funding Source : FDA OOPD Watson Pharmaceuticals</brief_summary>
	<brief_title>Triptorelin Ovary Protection Childhood Onset Lupus</brief_title>
	<detailed_description>Lupus autoimmune disease may harm organ body especially affect kidney , brain , skin lung . Cyclophosphamide effective medication treat lupus , damage ovary ( pair reproductive organ ) . Only female lupus patient may participate study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Females age 21 nonpregnant Tanner stage 2 determine physical examination breast stage Diagnosis SLE use updated American College Rheumatology ( ACR ) Classification Criteria SLE 1 Severe SLE require cyclophosphamide therapy Bone mineral density zscore &gt; 2.0 Must use medically acceptable form birth control study must pregnant screen visit No clinically significant abnormal finding consistent diagnosis childhoodonset SLE ( cSLE ) physical examination , medical history clinical laboratory result screen Currently combination medication must treat one dose cyclophosphamide gonadotoxic medication past Voluntary consent , age consent , assent participate study permission legal guardian Male patient age Female patient Tanner stage 1 Positive blood pregnancy test screen take oral injectable birthcontrol medication Prior exposure one dose gonadotoxic medication include cyclophosphamide History allergic adverse response triptorelin Diagnosed hypogonadism prior cyclophosphamide exposure Acutely lifethreatening disease activity prohibit inclusion clinical trial History clinically significant gastrointestinal tract , renal , hepatic , endocrine , oncologic , pulmonary ( asthma accept ) , cardiovascular disease ; history tuberculosis , epilepsy , diabetes , depression , psychosis , noncSLE condition , opinion physician , would jeopardize safety subject impact validity study result Patient age 18 year young severe depression define CDI ( Children 's Depression Inventory ) score &gt; 23 patient age 19 21 year severe depression define BDI ( Beck 's Depression Inventory ) score &gt; 29 Patient admits suicidal thought screen visit Bone mineral density lower z = 2.0 .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Ovarian damage</keyword>
	<keyword>Menopause</keyword>
</DOC>